Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
- PMID: 19520823
- DOI: 10.1182/blood-2009-04-213892
Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
Comment on
-
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.Blood. 2009 May 14;113(20):4992-5001. doi: 10.1182/blood-2008-09-178046. Epub 2009 Mar 5. Blood. 2009. PMID: 19264919 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources

